After closing an oversubscribed $85 million series B round, Quantx Biosciences Inc. is gearing up to begin clinical trials of its two lead immunology compounds, a STAT6 oral small-molecule inhibitor and an IL-17 oral small-molecule inhibitor.
A world-first pediatric mRNA cancer vaccine trial is launching in Australia that could open new possibilities for children with aggressive brain tumors.
A project that started as a bioreactor to assist astronauts in deep space to keep medications safe in a microgravity environment could help pharma companies model how drugs behave in the human body.
Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: Astrazeneca, Bio-Thera Solutions, Biogen, Daiichi Sankyo, Deciphera, Eisai, Ono, Peijia Medical, Racthera, Stada Arzneimittel, Sumitomo, Takeda, Telix.
Clinical updates for biopharma and med tech in Asia-Pacific, including data readouts and publications: Eccogene, Hengrui, Kailera, Lumosa, Merrylife, Mesoblast, Takeda, Yoltech.
RSS
.webp?height=488&t=1770931675&width=650 "Interleukin 17 (IL-17)")
